Poly Medicure Limited
Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate,
Phase-III, New Delhi - 110 020 (INDIA)
T: +91-11- 33550700, 47317000
E: info@polymedicure.com W: polymedicure.com
CIN: L40300DL1995PLC066923

Date: 05th November, 2026

Scrip Code: - 531768

The Manager,
BSE Limited,
Department of Corporate Services,
Phirozee Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

Scrip Code:- POLYMED

The Manager
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1-Block-G
Bandra Kurla Complex, Bandra(E),
Mumbai-400051.

Subject: Outcome of the Board Meeting of the Company

Ref: Compliance of Regulation 30 and 33 of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 05th November, 2026, at at 232-B, 3rd Floor, Okhla Industrial Estate, Phase-III, New Delhi - 110020, approved the following businesses:

1. **Financial Results**

a. Unaudited Financial Results (Consolidate & Standalone) for the Second quarter and half year ended on 30th September, 2026.

A signed copy of the above Financial Results (Standalone & Consolidated) along with Auditors' Review Reports thereon is attached herewith as **"Annexure – A"**

2. **Classification of Poly Medicure B.V., Netherlands ("POLYMED B.V.") as Material Subsidiary of the Company.**

In terms of Regulation 16(1)(c) read with Regulation 24 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations") Poly Medicure B.V., Netherlands, a Wholly Owned Subsidiary of the Company, has been identified as a Material Subsidiary of the Company, as its Net Worth has exceeded 10% of the consolidated networth of the Company. Accordingly, the Company shall ensure compliance with all applicable regulatory requirements prescribed under the Listing Regulations in relation to Material Subsidiaries.

The Meeting was started at 11:30 A.M. and concluded on 2:00 P.M.

Kindly take a note of the same for your further needful and oblige us.

Thanking You,
Yours Sincerely

For **Poly Medicure Limited**

AVINASH CHANDRA
Digitally signed by AVINASH CHANDRA
Date: 2026.11.05 14:06:47 +05'30'

Avinash Chandra
Company Secretary
M. No. A32270

POLY MEDICURE LTD. New Delhi

POLY MEDICURE LIMITED

Regd. Office: 232B, 3rd Floor, Okhla Industrial Estate Phase III, New Delhi - 110 020
Website: www.polymedicure.com, E-mail: investorcare@polymedicure.com, CIN: L40300DL1995PLC066923

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

(₹ in lacs except per share data)

	Particulars	Standalone					Consolidated					Standalone	Consolidated
		Quarter Ended			Half Year Ended		Quarter Ended			Half Year Ended		Year Ended	Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026	31.03.2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
1	**Income**												
a	Revenue from operations	48,827.62	43,109.95	41,654.17	91,937.57	80,058.84	58,052.56	52,537.55	44,388.16	1,10,590.11	84,709.23	1,66,246.48	1,87,525.92
b	Other income	2,043.66	2,863.64	3,372.10	4,907.30	7,524.36	1,900.93	3,339.58	3,394.43	5,240.51	7,606.23	11,991.77	12,008.22
	Total income (A)	**50,871.28**	**45,973.59**	**45,026.27**	**96,844.87**	**87,583.20**	**59,953.49**	**55,877.13**	**47,782.59**	**1,15,830.62**	**92,315.46**	**1,78,238.25**	**1,99,534.14**
2	**Expenses**												
a	Cost of materials consumed	18,226.92	15,274.60	14,431.91	33,501.52	27,306.77	20,156.91	18,387.50	15,706.96	38,544.41	29,814.31	53,885.50	59,938.70
b	Purchases of stock-in-trade	85.66	177.12	123.42	262.78	209.27	159.50	267.46	123.42	426.96	209.27	503.71	506.05
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(3,115.97)	(3,172.15)	(1,946.24)	(6,288.12)	(2,701.52)	(2,953.39)	(4,680.08)	(2,264.58)	(7,633.47)	(3,734.75)	(1,339.64)	(763.63)
d	Employee benefits expense	9,565.15	8,890.80	8,182.98	18,455.95	15,104.38	13,037.34	12,690.29	8,775.49	25,727.63	16,215.23	31,314.62	40,225.59
e	Research and development expenses	835.67	788.01	875.20	1,623.68	1,601.50	836.43	789.11	876.43	1,625.54	1,604.89	2,980.30	2,987.59
f	Finance cost	399.72	438.46	278.40	838.18	559.78	714.91	650.14	297.27	1,365.05	592.28	1,343.32	1,829.07
g	Depreciation and amortisation expense	2,725.90	2,647.00	2,426.35	5,372.90	4,721.84	3,504.89	3,625.28	2,504.44	7,130.17	4,841.46	9,789.82	11,551.66
h	Other expenses	9,840.71	9,065.81	8,853.65	18,906.52	17,274.17	13,059.14	12,572.19	9,690.62	25,631.33	18,538.04	34,291.11	40,399.97
	Total expenses (B)	**38,563.76**	**34,109.65**	**33,225.67**	**72,673.41**	**64,076.18**	**48,515.73**	**44,301.89**	**35,710.05**	**92,817.62**	**68,080.73**	**1,32,768.74**	**1,56,675.00**
3	**Profit before share of profit of associate, exceptional item and tax (A-B)**	**12,307.52**	**11,863.94**	**11,800.60**	**24,171.46**	**23,507.01**	**11,437.76**	**11,575.24**	**12,072.54**	**23,013.00**	**24,234.73**	**45,469.51**	**42,859.14**
4	Share of Profit of an associate	-	-	-	-	-	151.65	155.33	96.49	306.98	228.92	-	568.37
	Profit before exceptional item and tax	**12,307.52**	**11,863.94**	**11,800.60**	**24,171.46**	**23,507.01**	**11,589.41**	**11,730.57**	**12,169.03**	**23,319.98**	**24,463.65**	**45,469.51**	**43,427.51**
5	**Exceptional item**												
	Impact of Labour Codes/ Remeasurement of contingent consideration	-	-	-	-	-	(956.21)	-		(956.21)		680.40	680.40
6	**Profit before tax**	**12,307.52**	**11,863.94**	**11,800.60**	**24,171.46**	**23,507.01**	**12,545.62**	**11,730.57**	**12,169.03**	**24,276.19**	**24,463.65**	**44,789.11**	**42,747.11**
7	Tax expense												
a	Current tax	2,739.65	2,506.74	2,651.76	5,246.39	4,782.74	2,914.11	2,816.11	2,746.63	5,730.22	4,953.45	9,657.70	10,115.84
b	Deferred tax	365.37	543.91	243.79	909.28	1,026.33	118.93	386.07	242.65	505.00	1,022.19	1,502.75	528.11
c	Earlier year taxes	-	0.96	-	0.96	-	-	0.96	-	0.96	-	30.17	30.17
	Total tax expense	**3,105.02**	**3,051.61**	**2,895.55**	**6,156.63**	**5,809.07**	**3,033.04**	**3,203.14**	**2,989.28**	**6,236.18**	**5,975.64**	**11,190.62**	**10,674.12**
8	**Profit after tax**	**9,202.50**	**8,812.33**	**8,905.05**	**18,014.83**	**17,697.94**	**9,512.58**	**8,527.43**	**9,179.75**	**18,040.01**	**18,488.01**	**33,598.49**	**32,072.99**
9	**Other comprehensive income**												
	Items that will not be reclassified to profit or loss :												
	Remeasurements of defined benefit obligations	91.08	(90.94)	33.65	0.14	(83.67)	91.08	(90.94)	33.65	0.14	(83.67)	30.23	30.23
	Tax impacts on above	(22.93)	22.89	(8.47)	(0.04)	21.06	(22.93)	22.89	(8.47)	(0.04)	21.06	(7.61)	(7.61)
	Items that will be reclassified to profit or loss in subsequent period:												
	Exchange differences on translation of financial statements of foreign Subsidiaries	-	-	-	-	-	(209.18)	63.73	(49.57)	(145.45)	(30.50)	-	4,625.97
	Tax impacts on above						-	-	-				-
	Total other comprehensive income	**68.15**	**(68.05)**	**25.18**	**0.10**	**(62.61)**	**(141.03)**	**(4.32)**	**(24.39)**	**(145.35)**	**(93.11)**	**22.62**	**4,648.59**
10	**Total comprehensive income (comprising profit after tax and other comprehensive income after tax)**	**9,270.65**	**8,744.28**	**8,930.23**	**18,014.93**	**17,635.33**	**9,371.55**	**8,523.11**	**9,155.36**	**17,894.66**	**18,394.90**	**33,621.11**	**36,721.58**
11	**Net profit attributable to:**												
	Equity holders of the parent	-	-	-	-	-	**9,512.94**	**8,602.52**	**9,183.50**	**18,115.46**	**18,491.76**	-	**32,213.96**
	Non-controlling interests	-	-	-	-	-	(0.36)	(75.09)	(3.75)	(75.45)	(3.75)	-	(140.97)
12	**Other comprehensive income attributable to:**												
	Equity holders of the parent	-	-	-	-	-	**(139.99)**	**(4.35)**	**(24.39)**	**(144.34)**	**(93.11)**	-	**4,651.69**
	Non-controlling interests	-	-	-	-	-	(1.04)	0.03	-	(1.01)	-	-	(3.09)
13	**Total comprehensive income attributable to:**												
	Equity holders of the parent	-	-	-	-	-	**9,372.95**	**8,598.17**	**9,159.11**	**17,971.12**	**18,398.65**	-	**36,865.64**
	Non-controlling interests	-	-	-	-	-	(1.40)	(75.06)	(3.75)	(76.46)	(3.75)	-	(144.06)
14	Paid-up equity share capital (Face Value of ₹ 5 each)	5,068.07	5,067.97	5,067.97	5,068.07	5,067.97	5,068.07	5,067.97	5,067.97	5,068.07	5,067.97	5,067.97	5,067.97
15	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				3,15,104.42	-	-	-	-	-	-	3,00,203.27	3,05,549.30
16	Earnings per share (Quarterly not annualised) :												
	Basic (₹)	9.08	8.69	8.79	17.77	17.47	9.38	8.49	9.06	17.87	18.25	33.15	31.79
	Diluted (₹)	9.07	8.68	8.78	17.75	17.45	9.37	8.48	9.06	17.85	18.23	33.12	31.75

POLY MEDICURE LTD. New Delhi

DOOGAR & ASSOCIATES Chartered Accountants FRN : 000561N New Delhi

(₹ in Lacs)

Statement of Assets and Liabilities:		Standalone		Consolidated	
Particulars		As at 30.09.2026 (Unaudited)	As at 31.03.2026 (Audited)	As at 30.09.2026 (Unaudited)	As at 31.03.2026 (Audited)
ASSETS					
1	**Non-current assets**				
(a)	Property plant and equipment	1,24,895.37	1,20,018.88	1,34,996.05	1,25,515.09
(b)	Capital work-in-progress	10,983.28	9,031.40	10,968.49	9,051.37
(c)	Right of Use Asset	174.90	297.73	3,150.17	795.65
(d)	Goodwill on consolidation	-	-	31,572.65	31,369.99
(e)	Intangible assets	1,304.89	1,381.01	15,432.96	15,709.48
(f)	Intangible assets under development	612.47	553.13	989.80	820.14
(g)	Financial Assets				
	(i) Investment in subsidiaries/assodates	53,061.49	50,329.74	1,565.02	1,517.79
	(ii) Other Investments	1,263.51	60.54	1,263.51	60.54
	(iii) Other financial assets	1,840.34	1,806.30	1,853.65	1,859.33
(h)	Deferred tax Assets	-	-	3,848.14	3,652.59
(i)	Other non-current assets	6,337.64	7,559.07	6,586.98	7,611.04
Total non-current assets		**2,00,473.89**	**1,91,037.80**	**2,12,227.42**	**1,97,963.01**
2	**Current assets**				
(a)	Inventories	34,586.71	28,134.34	51,217.67	43,384.07
(b)	Financial assets				
	(i) Investments	71,806.55	73,915.75	71,806.54	73,915.74
	(ii) Trade receivables	47,431.26	44,224.73	55,888.11	53,117.27
	(iii) Cash and cash equivalents	769.70	593.81	5,820.79	5,122.82
	(iv) Bank Balances other than (iii) above	3,992.98	3,664.18	4,137.98	3,664.18
	(v) Loans	496.43	70.95	68.45	74.43
	(vi) Other financial assets	4,095.90	4,075.34	1,024.87	4,270.36
(c)	Other current assets	12,071.49	9,277.99	13,337.92	10,344.84
(d)	Current Tax Assets (Net)	-	-	-	-
Total current assets		**1,75,251.02**	**1,63,957.09**	**2,03,302.33**	**1,93,893.71**
TOTAL ASSETS		**3,75,724.91**	**3,54,994.89**	**4,15,529.75**	**3,91,856.72**
EQUITY AND LIABILITIES					
EQUITY					
(a)	Equity share capital	5,068.07	5,067.97	5,068.07	5,067.97
(b)	Other equity	3,15,104.42	3,00,203.27	3,21,466.84	3,05,549.30
Equity attributable to shareholders of the company		**3,20,172.49**	**3,05,271.24**	**3,26,534.91**	**3,10,617.27**
Non-controlling interest				**4,230.59**	**4,307.05**
Total equity		**3,20,172.49**	**3,05,271.24**	**3,30,765.50**	**3,14,924.32**
LIABILITIES					
1	**Non-current liabilities**				
(a)	Financial liabilities				
	(i) Borrowings	21.51	252.81	3,910.93	5,208.77
	(ii) Lease Liabilities	62.02	92.53	2,630.08	516.11
	(iii) Other financial liabilities	71.49	77.31	2,316.25	3,593.35
(b)	Other Non current liabilities			806.39	1,000.75
(c)	Provisions	1,430.65	1,420.75	3,385.56	3,106.70
(d)	Government Grants	60.52	156.05	61.58	157.58
(e)	Deferred tax liabilities (Net)	6,706.23	5,796.90	6,725.24	5,796.90
	Total non-current liabilities	**8,352.42**	**7,796.35**	**19,836.03**	**19,380.16**

POLY MEDICURE LTD. New Delhi

DOOGAR & ASSOCIATES * Chartered Accountants * FRN : 000561N New Delhi

3	**Current liabilities**				
(a)	Financial liabilities				
	(i) Borrowings	28,242.21	24,590.14	33,803.53	28,952.98
	(ii) Lease Liabilities	128.66	226.46	841.14	679.73
	(iii) Trade payables				
	a) total outstanding dues of micro enterprises and small enterprises	975.49	1,596.58	975.49	1,596.58
	b) total outstanding dues of creditors other than micro enterprises and small enterprises	8,599.39	6,874.37	12,293.37	10,669.93
	(iv) Other financial liabilities	6,381.15	5,745.78	9,831.49	8,894.08
(b)	Other current liabilities	1,661.55	2,313.08	5,513.15	5,642.95
(c)	Provisions	45.71	23.79	45.71	256.03
(d)	Current Tax Liabilities (Net)	1,165.84	557.10	1,624.24	859.96
	Total Current Liabilities	**47,200.00**	**41,927.30**	**64,928.22**	**57,552.24**
TOTAL EQUITY AND LIABILITIES		**3,75,724.91**	**3,54,994.89**	**4,15,529.75**	**3,91,856.72**

DOOGAR & ASSOCIATES * Chartered Accountants * FRN : 000561N New Delhi

POLYCAB WIRES LTD. New Delhi

(₹ in Lacs)

Cash Flow Statement for the half year ended 30 September 2026	Standalone		Consolidated	
Particulars	Half Year ended		Half Year ended	
	30 September 2026	30 September 2025	30 September 2026	30 September 2025
	Unaudited	Unaudited	Unaudited	Unaudited
A CASH FLOWS FROM OPERATING ACTIVITIES				
Profit before tax	24,171.46	23,507.01	24,276.18	24,463.65
Adjusted for:				
Depreciation and amortisation	5,372.90	4,721.84	7,130.17	4,841.46
Share in Income from Associate	-	-	(306.98)	(228.92)
Interest expense	838.18	559.78	1,365.05	592.28
Dividend Income/governing council share	(318.95)	-	(1.07)	-
Interest income	(250.40)	(699.51)	(250.40)	(699.51)
Loss/(profit) on assets sold/ discarded	0.80	43.87	7.98	43.87
Debts/advances written off	23.30	26.27	23.30	26.27
Provision for doubtful debts and advances	11.06	50.28	91.22	50.28
Credit balances no longer required, written back	(16.24)	(19.23)	(16.24)	(19.23)
Deferred employee compensation expenses (net)	431.93	312.48	431.93	312.48
Unrealised foreign exchange (gain) /loss	1,006.31	(694.80)	1,006.31	(694.80)
Realised and unrealised (Gain)/Loss on Mutual Fund	(2,748.69)	(4,214.16)	(2,748.69)	(4,214.16)
Other Comprehensive Income				
Ind AS & Other adjustments	(171.09)	(130.92)	(282.65)	(243.74)
Effect of foreign exchange rates on translation of operating cashflows			(537.04)	
Operating profit before working capital changes	**28,350.57**	**23,462.90**	**30,189.07**	**24,229.93**
Movement in working capital				
Decrease/(increase) in inventories	(6,452.37)	(2,881.59)	(7,833.59)	(3,905.02)
Decrease/ (increase) in Trade Receivable	(4,326.12)	(4,602.07)	(3,970.58)	(4,997.57)
Decrease/(Increase) in financial assets	244.68	230.79	232.06	88.01
Decrease/(Increase) in other assets	(3,503.67)	(556.23)	(3,182.80)	(377.53)
Increase/ (decrease) in trade payables	1,211.34	1,804.08	1,092.20	1,895.09
Increase/ (decrease) in other financial liabilities	925.73	(2,673.15)	(92.18)	(5,127.09)
Increase/ (decrease) in other liabilities	(960.41)	(1,106.51)	(635.08)	1,411.33
Increase/ (decrease) in provisions	31.96	159.79	68.69	309.07
Cash generated from operations	**15,521.71**	**13,838.02**	**15,867.79**	**13,526.12**
Direct taxes paid (net of refunds)	(4,638.61)	(4,233.49)	(4,966.90)	(4,381.86)
Net cash from operating activities (A)	**10,883.10**	**9,604.53**	**10,900.89**	**9,144.26**
B CASH FLOWS FROM INVESTING ACTIVITIES				
Purchase of fixed assets (including capital advances)	(10,788.01)	(15,459.25)	(12,428.68)	(15,733.12)
Investment in subsidiary	(2,731.75)	(16,931.20)		
Payments towards business acquisition (net of cash and cash equivalents acquired upon business acquisition)		-	(29.65)	(15,059.34)
Advance paid to subsidiary	(9.25)			
Amount paid under resolution plan pending transfer of control	-	(3,316.00)	-	(3,316.00)
(Purchase)/Sale of current Investments (net)	3,642.28	19,325.02	3,642.28	19,325.02
Proceeds from / (Investment in) Fixed Deposits (net)	(347.46)	2,158.97	(347.46)	2,158.97
Proceeds from sale of Property plant and equipment & investment properties	5.66	44.74	45.28	44.74
Dividend Income/governing council share	139.18	-	139.18	-
Interest income	167.52	282.74	167.52	282.74
Net cash used for investing activities (B)	**(9,921.83)**	**(13,894.98)**	**(8,811.53)**	**(12,296.99)**
C CASH FLOWS FROM FINANCING ACTIVITIES				
Proceeds from (Repayment) of borrowings / deferred payment liabilities (net)	3,386.52	5,256.76	3,457.26	5,586.80
Proceeds from Share Allotments ESOP	1.98	33.78	1.98	33.78
Repayment of Lease Liabilities including interest	(140.28)	(130.88)	(570.53)	(130.88)
Dividend Paid (including unclaimed dividend transferred)	(3,229.13)		(3,229.13)	-
Interest / Finance charges paid	(804.47)	(532.65)	(1,075.73)	(562.56)
Net cash from/(used for) financing activities (C)	**(785.38)**	**4,627.00**	**(1,416.15)**	**4,927.14**
Net increase/(decrease) in cash and cash equivalents (A+B+C)	**175.89**	**336.55**	**673.21**	**1,774.41**
Cash and cash equivalents at the beginning of the year	**593.81**	**54.85**	**5,122.82**	**869.89**
Effect of foreign exchange rate changes on cash and cash equivalents held in foreign currency			24.75	-
Cash and cash equivalents at the end of the period	**769.70**	**391.40**	**5,820.79**	**2,644.30**
COMPONENTS OF CASH AND CASH EQUIVALENTS				
Balances with Banks in current account	759.22	381.73	5,806.80	2,624.47
Cash on hand	10.48	9.67	13.99	19.83
Cash and cash equivalents at the end of the period	**769.70**	**391.40**	**5,820.79**	**2,644.30**

Note: The above statement of cash flow has been prepared under indirect method as set out in IND AS-7 "Statement of Cash Flow"

DOOGAR & ASSOCIATES * Chartered Accountants * FRN : 000561N New Delhi

POLY MEDICURE LTD. New Delhi

Notes:

1 The above unaudited standalone and consolidated results were reviewed and recommended by the Audit Committee & approved by the Board of Directors at their respective meetings held on 5th November, 2026 and have also been limited reviewed by the statutory auditors of the Company. The statutory auditors have expressed an unmodified review report on these standalone and consolidated financial results.

2 The standalone and consolidated financial results have been prepared in accordance with the principles and procedures of Indian Accounting Standards ("Ind AS") as notified under the Companies (Indian Accounting Standards) Rules, 2015 as specified in section 133 of the Companies Act, 2013.

3 The consolidated financial results of the company and its foreign subsidiaries/Indian subsidiary ("Group") and associate have been prepared as per IND AS 110 "Consolidated Financial Statements" and IND AS 28 on "Investment in Associates". The entities whose financial statements have been included in consolidated financial statements are as annexed.

4 In line with the provisions of Ind AS 108 "Operating Segments" and on the basis of review of operations being done by the management of the company, the operations of the group falls under medical devices, which is considered to be the only reportable segment by the management.

5 During the half year ended 30th September, 2026, Polymed Brazil LTDA, a wholly owned subsidiary company has acquired 100% equity in Medyneo Comercio De Produtos Para Saude LTDA at a total consideration of ₹ 34.08 lacs effective from 29th April, 2026.

6 During the previous year ended 31st March, 2025, the company had issued 53,19,148 equity shares of ₹ 5/- each at premium of ₹ 1,875/- each (issue price per share ₹ 1,880/- each) amounting to ₹ 99,999.98 lacs to Qualified Institutional Investors on QIP basis and allotment was completed on 22nd August, 2024. The proceeds of QIP have been utilized as per objects of issue and the unutilised amount of ₹ 40,421.43 lacs have temporarily been invested in liquid mutual funds/FD/bonds and balance amount in QIP account is ₹ 7.10 lacs.

7 The Consolidated financial statement for the quarter and half year ended 30th September 2026 includes ₹ 956.21 lacs towards derecognition of fair value of contingent consideration payable by one of the step-down subsidiary to the Selling Shareholder of the "Pendracare Group". This derecognition was on account of non-achelvement of the agreed milestone for earn-out payment as agreed under the Share Purchase Agreement. This event being the event after the acquisition date, hence the liability derecognised is classified as an exceptional item.

During the quarter ended 30th September 2025, M/s Poly Medicure BV, Netherlands, a wholly owned subsidiary company of the Company, acquired 90% controlling stake in Risor Holding B.V, Netherlands for a cash consideration of ₹ 14,825.77 lacs effective from 23rd September 2025. During the period ended 30th September 2025, this transaction was accounted for in accordance with the acquisition method. The Purchase price allocation which was earlier done on a provisional basis, was finalised in quarter ended 30th September 2025, accordingly, the amount of goodwill and other recoverable have been inter-se adjusted retrospectively by ₹ 267.56 lacs and goodwill as on acquisition date is restated to ₹ 16,395.13 lacs. During the quarter ended 31st December 2025, M/s Poly Medicure B.V, Netherlands has acquired 100% stake in Medistream SA, Switzerland for an upfront consideration of ₹ 24,322.83 lacs and this transaction was accounted in accordance with Ind AS 103, "Business Combinations". Remeasurement adjustment in amount of goodwill and deferred tax asset has been carried out and the amount of goodwill is retrospectively carried at ₹ 9,782.58 lacs and deferred tax assets at ₹ 2,533.59 lacs on acquisition date.

8 Upon consolidation of Himalayan Mineral Waters Private Limited, effective 1st April 2026, the excess of fair value of assets acquired over the total consideration paid in respect of Himalayan Mineral Waters Private Limited, amounting to ₹ 1,277.61 lacs have been taken as capital reserve as on 1st April 2026.

9 Previous period figures have been regrouped wherever necessary to conform to the current year classification.

10 The unaudited results of Poly Medicure Limited for the quarter ended 30th September 2026 are available on our website, www.polymedicure.com and on the Stock Exchange website www.nseindia.com and www.bseindia.com.

Place : New Delhi
Date : 5th November 2026

DOOGAR & ASSOCIATES * Chartered Accountants * FRN : 000561N New Delhi

POLY MEDICURE LTD. New Delhi

Himanshu Baid
Managing Director

List of entities included in the consolidated financial statements for the quarter ended 30th September, 2026 are as under:

Sr. No.	Name of the Company	Country of incorporation	Holding as on September 30, 2026	Holding as on March 31, 2026
	Parent Company			
1	Poly Medicure Limited			
	Subsidiary			
2	Plan 1 Health India Private Limited[1]	India	100%	100%
3	Poly Medicure (Laiyang) Company Limited[1]	China	100%	100%
4	Poly Medicure B.V.[1]	Netherlands	100%	100%
5	Polymed Brazil LTDA[1]	Brazil	100%	100%
6	Himalayan Mineral Waters Private Limited[1]	India	100%	-
	Step - subsidiary			
7	Plan 1 Health SRL[2]	Italy	100%	100%
8	Risor Holding B.V.[2]	Netherlands	90%	90%
9	Wellinq Medical B.V.[3]	Netherlands	100%	100%
10	Pendracare Holding B.V.[3]	Netherlands	100%	100%
11	Pendracare Vascular B.V.[4]	Netherlands	100%	100%
12	Pendracare International B.V.[4]	Netherlands	100%	100%
13	Medistream SA[2]	Switzerland	100%	100%
14	Citieffe SRL[5]	Italy	100%	100%
15	Citieffe Inc.[6]	USA	100%	100%
16	Citieffe De.[6]	Mexico	100%	100%
17	Poly Health Inc.[2]	USA	100%	100%
18	Poly Health Limited[2]	UK	100%	100%
19	Medyneo Comercio De Produtos Para Saude LTDA[7]	Brazil	100%	-
	Associate			
20	Ultra For Medical Products Company (Ultra Med)	Egypt	23%	23%

[1] Wholly-owned subsidiary of Poly Medicure Limited

[2] Wholly-owned subsidiary of Poly Medicure B.V.

[3] Wholly-owned subsidiary of Risor Holding B.V.

[4] Wholly-owned subsidiary of Pendracare Holding B.V.

[5] Wholly-owned subsidiary of Medistream SA

[6] Wholly-owned subsidiary of Citieffe SRL

[7] Wholly-owned subsidiary of Polymed Brazil LTDA

POLY MEDICURE LTD. New Delhi

DOOGAR & ASSOCIATES * Chartered Accountants * FRN. 000561N New Delhi

Independent Auditors' Review Report on the Quarterly and Year to date Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To
Board of Directors
Poly Medicure Limited
232-B, IIIrd Floor,
Okhla Industrial Estate, Phase-III,
New Delhi- 110020

We have reviewed the accompanying statement of unaudited standalone financial results of Poly Medicure Limited ("the company") for the quarter and half year ended 30th September 2026 attached herewith, being submitted by the company pursuant to the requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). This statement is the responsibility of the Company's Management and approved by the Board of Directors has been compiled from the related interim financial statements which has been prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI Circular dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Doogar & Associates
Chartered Accountants
Firm Registration No. 000561N



Madhusudan Agarwal
Partner
Membership No. 086580
UDIN: 26086580PTBSHJ5044

Place: New Delhi
Date: 05 November 2026

Independent Auditors' Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To
Board of Directors
Poly Medicure Limited
232-B, IIIrd Floor,
Okhla Industrial Estate, Phase-III,
New Delhi- 110020

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Poly Medicure Limited (" Parent") and its subsidiaries (the parent and its subsidiaries together referred to as 'the group') and its share of the profit after tax of its associate for the quarter and half year ended 30th September 2026 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended ('the Regulation'), read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019('the Circular').

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards 34, (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Regulation, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the statement.

5. We did not review the financial results of one foreign subsidiary namely Polymed Brazil LTDA (consolidated) and two wholly owned subsidiary incorporated in India namely Himalayan Mineral Waters Private Limited and Plan 1 Health India Private Limited included in the consolidated unaudited financial results, whose financial results without elimination reflects total assets of Rs. 626.90 lacs as at 30th September 2026, total revenue of Rs. Nil and Rs. Nil, total net profit/ (loss) after tax of Rs. (144.13) lacs and Rs. (268.54) lacs, and total comprehensive income/ (loss) of Rs.

(144.13) lacs and Rs. (268.54) lacs, for the quarter and period ended 30th September 2026 respectively, as considered in the consolidated unaudited financial results.

The consolidated unaudited financial results also include the Group's share of profit after tax of Rs. 151.65 lacs and Rs. 306.98 lacs, included in quarter and period ended 30th September 2026 respectively, as considered in the statement, in respect of one foreign associate, whose financial results have not been reviewed by us.

These financial results are certified by the management of respective companies and our conclusion on the Statement in so far as it relates to the amounts and disclosures in respect of these subsidiaries and associate is based solely on the basis of financial statement as certified and procedures performed by us as stated in paragraph 3 above. Our conclusion on the statement is not modified in respect of above matter.

We did not review the financial results of one foreign subsidiary namely Poly Medicure (Laiyang) Co Limited, China, wholly owned subsidiary company of the Company included in the consolidated unaudited financial results, whose financial statements without elimination reflects total assets of Rs. 1,307.60 lacs as at 30th September 2026, total revenue of Rs. 187.89 lacs and Rs. 347.57 lacs, total net profit/ (loss) after tax of Rs. (2.27) lacs and Rs. (59.59) lacs, and total comprehensive income/ (loss) of Rs. (2.27) lacs and Rs. (59.59) lacs, for the quarter and period ended 30th September 2026 respectively and have been limited reviewed by auditor situated outside India. Our opinion on consolidated financial statements in so far as it relates to the aforesaid subsidiary is based on limited review report of the subsidiary. Our conclusion on the statement is not modified in respect of above matter.

We did not review the Consolidated Financial Statement of one foreign subsidiary namely Poly Medicure BV Netherlands, which includes financial statements of Plan 1 Health SRL Italy for quarter and period ended 30th June 2026 and Poly Health Medical Inc. US, Poly Health Limited UK for the quarter and period ended 30th September 2026 and whose financial statement without elimination reflect total assets of Rs. 11,354.36 lacs as at 30th September 2026, total revenue of Rs. 4,540.30 lacs and Rs. 7,969.55 lacs, Net profit after tax of Rs. 123.49 lacs and Rs. 164.41 lacs and total comprehensive income/ (loss) of Rs. 123.49 lacs and Rs. 164.41 lacs, for the quarter and period ended 30th September 2026 respectively and have been limited reviewed by auditor situated outside India/ in India and also includes financial statement of Risor Holding B.V. Netherlands (consolidated) and Medistream SA Switzerland (consolidated), whose financial statement without elimination reflect total assets of Rs. 53,293.90 lacs as at 30th September 2026, total revenue of Rs. 6,779.24 lacs and Rs. 14,409.32 lacs, total profit/ (loss) after tax of Rs. (1,050.69) lacs and Rs. (1,554.96 lacs) and total comprehensive income/ (loss) of Rs. (1,050.69) lacs and Rs. (1,554.96 lacs), for the quarter and period ended 30 September 2026 respectively and have been management certified and given effect to in consolidated financial statements. Our opinion on consolidated financial statements in so far as it relates to the aforesaid subsidiary is based on limited review report of three step down subsidiaries and management certified financial statements of other step down subsidiaries. Our conclusion on the statement is not modified in respect of above matter.

6. In respect of subsidiaries and associate located outside India whose financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and are management certified/ limited reviewed. The Parent's management has converted the financial results of such subsidiaries and associate located outside India from accounting principles generally accepted in their respective countries to the accounting principles generally accepted in India. We have reviewed conversion adjustments made by the parent's management. Our conclusion in so far as it relates to balances and affairs of such subsidiaries and associate located outside India is based on the conversion adjustments prepared by the management of the Parent and reviewed by us.



7. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the financial statements as limited reviewed/ certified by the management referred to paragraph 5 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid in the aforesaid Indian Accounting Standard specified under Section 133 of Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Doogar & Associates
Chartered Accountants
Firm's Registration number: 000561N

DOOGAR & ASSOCIATES F.R.N. 000561N New Delhi Chartered Accountants

Madhusudan Agarwal
Partner
Membership number: 086580
UDIN: 26086580IRYWFN6590

Place: New Delhi
Date: 05 November 2026

Annexure – 1

List of entities included in the consolidated financial statements for the quarter/period ended 30th September, 2026 are as under:

Sr. No.	Name of the Company	Country of incorporation
	Parent Company	
1	Poly Medicure Limited	
	Subsidiary	
2	Plan 1 Health India Private Limited[1]	India
3	Poly Medicure (Laiyang) Company Limited[1]	China
4	Poly Medicure B.V.[1]	Netherlands
5	Polymed Brazil LTDA[1]	Brazil
6	Himalayan Mineral Waters Private Limited[1]	India
	Step - subsidiary	
7	Plan 1 Health SRL[2]	Italy
8	Risor Holding B.V.[2]	Netherlands
9	Wellinq Medical B.V.[3]	Netherlands
10	Pendracare Holding B.V.[3]	Netherlands
11	Pendracare Vascular B.V.[4]	Netherlands
12	Pendracare International B.V.[4]	Netherlands
13	Medistream SA[2]	Switzerland
14	Citieffe SRL[5]	Italy
15	Citieffe Inc.[6]	USA
16	Citieffe De.[6]	Mexico
17	Poly Health Inc.[2]	USA
18	Poly Health Limited[2]	UK
19	Medyneo Comercio De Produtos Para Saude LTDA[7]	Brazil
	Associate	
20	Ultra For Medical Products Company (Ultra Med)	Egypt

[1] Wholly-owned subsidiary of Poly Medicure Limited
[2] Wholly-owned subsidiary of Poly Medicure B.V.
[3] Wholly-owned subsidiary of Risor Holding B.V.
[4] Wholly-owned subsidiary of Pendracare Holding B.V.
[5] Wholly-owned subsidiary of Medistream SA
[6] Wholly-owned subsidiary of Citieffe SRL
[7] Wholly-owned subsidiary of Polymed Brazil LTDA

DOOGAR & ASSOCIATES * Chartered Accountants * FRN : 000561N New Delhi